TY - JOUR T1 - A Polymorphism in the <strong><em>CYP17</em></strong> Gene and Risk of Prostate Cancer JF - Cancer Epidemiology Biomarkers &amp; Prevention JO - Cancer Epidemiol Biomarkers Prev SP - 243 LP - 247 VL - 11 IS - 3 AU - Stanford, Janet L. AU - Noonan, Elizabeth A. AU - Iwasaki, Lori AU - Kolb, Suzanne AU - Chadwick, Robert B. AU - Feng, Ziding AU - Ostrander, Elaine A. Y1 - 2002/03/01 UR - http://cebp.aacrjournals.org/content/11/3/243.abstract N2 - Steroid hormones are important in the etiology and progression of prostate cancer, and expression of genes involved in hormone production may alter susceptibility. One such gene is CYP17, which encodes the cytochrome P450c17a enzyme responsible for the biosynthesis of testosterone. A T to C transition (A2 allele) in the 5′ promoter region of the gene is hypothesized to increase the rate of gene transcription, increase androgen production, and thereby increase risk of prostate cancer. To test this hypothesis, germ-line DNA samples from a large population-based study of incident prostate cancer cases (n = 590) and controls (n = 538) of similar age without the disease were genotyped. The frequency of the A2 allele was similar in cases and controls. Compared with men with the A1/A1 genotype, the adjusted odds ratio was 0.81 for the A1/A2 and 0.87 for the A2/A2 genotype. Risk estimates did not vary substantially by age or race. However, stratification by family history of prostate cancer revealed that among white men with an affected first-degree relative, homozygotes for the A2 allele had a significant elevation in risk (odds ratio = 19.2; 95% confidence interval, 2.2–157.4) compared with men who were homozygous for the A1 allele (interaction P = 0.0005). These results suggest that the CYP17 A2/A2 genotype predicts susceptibility to prostate cancer in white men with a family history of the disease. It is also possible that CYP17 interacts with other genes that influence risk of familial prostate cancer. ER -